SCHEMBL24409244

SCHEMBL24409244

Cn1cccc1-c1ccc(C=O)cn1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.42
TRIM33 Q9UPN9 1/20 0.42
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALOX15 P16050 1/20 0.39
ALDH1A1 P00352 4/20 0.39
CYP2A6 P11509 3/20 0.39
CYP2A13 Q16696 1/20 0.39
CYP11B1 P15538 1/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.36
KCNJ1 P48048 1/20 0.36
SIGMAR1 Q99720 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
PCSK9 Q8NBP7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30630797 1.00 TRIM24 (0.42) TRIM24TRIM33MEN1KMT2AALOX15
SCHEMBL1356310 0.74 ALDH1A1 (0.44) ALDH1A1CYP2A6CYP11B1KDM4EKCNJ1
SCHEMBL21873379 0.73 JMJD6 (0.41) MEN1KMT2AALDH1A1CYP11B1KDM4E
SCHEMBL16880609 0.73 HSP90AA1 (0.51) ALDH1A1CYP11B1KDM4EPOLB
SCHEMBL30630858 0.73 HSP90AA1 (0.51) ALDH1A1CYP11B1KDM4EPOLB
SCHEMBL31607177 0.72 ALDH1A1 (0.43) ALDH1A1CYP2A6CYP11B1KDM4EKCNJ1
SCHEMBL31607172 0.72 ALDH1A1 (0.43) ALDH1A1CYP2A6CYP11B1KDM4EKCNJ1
SCHEMBL31607175 0.72 ALDH1A1 (0.43) ALDH1A1CYP2A6CYP11B1KDM4EKCNJ1
SCHEMBL14762040 0.70 AOC3 (0.37) MEN1KMT2AALDH1A1CYP2A6CYP11B1
SCHEMBL5181284 0.70 DYRK1A (0.46) TRIM24TRIM33ALOX15ALDH1A1CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220144847-A1 HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF ELLIPSES PHARMA LTD (GB) 2022-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144847-A1 HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF NOTUM, FURIN, CYP4A11 TRIM24 4398/4885TRIM33 4701/4885MEN1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.